The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of nab-rapamycin versus rapamycin in colorectal cancer cell lines and associations with KRAS and PI3K mutations.
H. F. Kennecke
Research Funding - Celgene
M. Rahman
No relevant relationships to disclose
S. Yip
No relevant relationships to disclose
R. Woods
No relevant relationships to disclose
D. Schaeffer
No relevant relationships to disclose
I. Tai
No relevant relationships to disclose